抑制HB-EGF的多种策略:与受体结合的干扰,生殖区脱落和母细胞信号的干扰
Andrii Siromolot1, Dariia Zhukova2, Svitlana Romaniuk2
1Department of Molecular Immunology, Palladin Institute of Biochemistry of the NAS of Ukraine, 9 Leontovycha Street, Kyiv, 01054, Ukraine; Department of Technologies of Medical Diagnostics and Treatment, ESC "Institute of Biology and Medicine" of Taras Shevchenko National University of Kyiv, 2 Hlushkova Avenue, Kyiv, 03022, Ukraine.
Biochimie
|February 15, 2026
概括
无毒的甲状腺毒素类似物CRM197和SbB阻断结合氨酸的EGF类生长因子 (HB-EGF) 从结合瘤细胞受体. 结合HB-EGF向策略可能会减少癌细胞的增殖,并诱导细胞死亡.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 肝素结合EGF类似生长因子 (HB-EGF) 信号传递与瘤细胞增殖和存活有关.
- 针对HB-EGF与其受体 (如EGFR) 的相互作用及其细胞外基质相互作用提供了潜在的治疗策略.
- 疹毒素类似物可以被设计成干扰生长因子信号通路.
研究的目的:
- 为了评估复合喉毒素类似物CRM197和B亚单元 (SbB) 抑制HB-EGF与瘤细胞受体结合的疗效.
- 评估HB-EGF-heparan硫酸盐蛋白质糖 (HSPG) 相互作用和蛋白酶抑制剂对细胞增殖的影响.
- 研究HB-EGF向策略对潜在的癌症治疗的综合效应.
主要方法:
- 使用流细胞计量测量光HB-EGF衍生物在CRM197和SbB的存在下与细胞的结合.
- 使用MTT测试来评估由HB-EGF-HSPG相互作用和蛋白酶抑制剂抑制细胞增殖.
- 进行了组合指数 (CI) 计算,以评估不同治疗剂之间的协同作用或对抗作用.
主要成果:
- CRM197和SbB有效地阻断了可溶性HB-EGF (sHB-EGF) 与细胞表面受体的结合.
- 蛋白酶抑制剂对癌细胞表现出细胞静止和细胞毒性作用.
- 氨酸没有增强细胞增殖,这表明它隔离HB-EGF并阻止受体相互作用.
结论:
- 再组合的甲状腺毒素类似物CRM197和SbB是HB-EGF受体相互作用的有效抑制剂.
- 通过受体结合和ectodomain shedding抑制向HB-EGF,为减少癌细胞增殖提供了一个可行的策略.
- 结合HB-EGF向方法在高EGFR和亲HB-EGF表达的瘤中诱导癌细胞死亡具有前景.
相关概念视频
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Receptor Downregulation in MVBs
2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.9K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.7K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.7K
TGF - β Signaling Pathway
10.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
Regulation of Angiogenesis and Blood Supply
3.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.6K
Amplifying Signals via Enzymatic Cascade
18.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
18.7K


